Company Profile

Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.

Employees

1,760

Sector

Pharmaceuticals

More about the company

04/09	Abcam And Genedata Collaborate To Accelerate AI-Driven Antibody Development At Global Scale	CI
23/07	Abcam Limited Appoints Kaveh Kahen as Director, Effective July 14, 2026	CI
18/06	ABCAM LIMITED Announces Termination of Markus Lusser as Director, Effective June 5, 2026	CI
28/04	Wall Street's Rally Looks More Fragile as Inflation Risks Build
14/04	Abcam Launches SimpleStep Ignite ELISA	CI
10/03	Abcam Limited Appoints Melanie Hammerschmidt-Broman as Director, Effective March 10, 2026	CI
21/01	Abcam Joins the Innovative Health Initiative LIGAND-AI Project to Advance Artificial Intelligence (AI)-Driven Drug Discovery Through Open Science	CI
12/01	Abcam Limited Announces Termination of Knud Mueller as Director, Effective December 31, 2025	CI
22/10/25	Molecular Instruments and Abcam Announce Broad Compatibility of the HCR HiFi Encoder with Abcam?s Rabmab and Mouse Antibody Portfolio	CI
07/12/23	Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...
07/12/23	Job losses delight investors
07/12/23	Danaher Closes Acquisition of Abcam	MT
07/12/23	Danaher completes $5.7 billion acquisition of Abcam	RE

31/10/23	RBC Trims Price Target on Abcam to $24 From $25, Keeps Sector Perform Rating	MT
30/08/23	SVB Securities Downgrades Abcam to Market Perform From Outperform, Price Target is $24	MT
29/08/23	Deutsche Bank Raises Abcam Price Target to $23.50 From $17, Maintains Hold Rating	MT
06/07/23	RBC Raises Abcam's Price Target to $25 From $22, Notes Strong Margin at H1; Keeps Sector Perform Rating	MT
20/06/23	RBC Downgrades Abcam to Sector Perform From Outperform, Trims Price Target to $22 From $23 After Recent Stock Jump, Sees 'Material Volatility'	MT

06/12/23	Danaher Completes Acquisition of Abcam	PR
05/12/23	Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales	BU
20/11/23	Abcam Acquisition by Danaher has received all Identified Clearances, Transaction Expected to Close on December 6, 2023	AQ
17/11/23	Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023	BU
07/11/23	Shareholders of Abcam Approve Proposed Acquisition by Danaher	BU

28/04	Wall Streets Rally wirkt angesichts steigender Inflationsrisiken fragiler
28/04	La racha de Wall Street se debilita ante el repunte de los riesgos inflacionistas
06/12/23	USA-Les valeurs à suivre à Wall Street (actualisé)
07/11/23	USA-Les valeurs à suivre à Wall Street (actualisé)
29/08/23	Aktien New York Schluss: Weitere Erholung - Anleger warten auf Daten

Manager	Title	Age	Since
Alan Hirzel CEO	Chief Executive Officer	58	09/09/2014
Markus Lusser PSD	President	58	18/03/2024
Tommy J. Thomas IRC	Investor Relations Contact	-	27/06/2022

Abcam Stock OTC Markets

Stocks

ABCZF

GB00B6774699

Pharmaceuticals

Latest news: Abcam

Analysts' recommendations: Abcam

Press Releases: Abcam

News in other languages: Abcam

Quotes and Performance

Managers and Directors: Abcam

Biopharmaceuticals

Company Profile

Director	Title	Age	Since
Alan Hirzel BRD	Director/Board Member	58	01/01/2014
Mara Aspinall BRD	Director/Board Member	63	14/09/2015
Giles Kerr BRD	Director/Board Member	67	12/12/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCAM	+0.68%	+0.68%	-	-	5.52B
ELI LILLY AND COMPANY	+1.08%	+1.99%	+58.03%	+129.10%	1,143B
JOHNSON & JOHNSON	+1.32%	+5.72%	+45.79%	+85.36%	647B
ABBVIE INC.	+0.74%	+1.12%	+26.57%	+102.97%	506B
ROCHE HOLDING AG	+0.16%	+1.91%	+53.01%	+65.56%	384B
MERCK & CO., INC.	-0.22%	-5.31%	+63.07%	+38.22%	350B
NOVARTIS AG	+1.07%	+2.84%	+31.97%	+54.18%	293B
ASTRAZENECA PLC	+0.41%	+2.12%	+3.84%	+26.07%	265B
AMGEN INC.	+1.33%	+3.39%	+55.16%	+72.20%	242B
GILEAD SCIENCES, INC.	+0.80%	+4.28%	+35.86%	+105.93%	197B
Average	+0.74%	+0.85%	+41.48%	+75.51%	447.5B
Weighted average by Cap.	+0.86%	+0.71%	+45.35%	+88.04%